32.00
0.80 (2.56%)
| Previous Close | 31.20 |
| Open | 31.37 |
| Volume | 273,646 |
| Avg. Volume (3M) | 657,350 |
| Market Cap | 1,244,784,000 |
| Price / Book | 7.87 |
| 52 Weeks Range | |
| Earnings Date | 31 Oct 2024 - 4 Nov 2024 |
| Diluted EPS (TTM) | -2.17 |
| Total Debt/Equity (MRQ) | 1.31% |
| Current Ratio (MRQ) | 20.95 |
| Operating Cash Flow (TTM) | -58.62 M |
| Levered Free Cash Flow (TTM) | -33.76 M |
| Return on Assets (TTM) | -24.04% |
| Return on Equity (TTM) | -36.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Longboard Pharmaceuticals, Inc. | Mixed | Bullish |
Stockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.75 |
|
Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.31% |
| % Held by Institutions | 119.36% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 90.00 (Cantor Fitzgerald, 181.25%) | Buy |
| Median | 60.00 (87.50%) | |
| Low | 44.00 (Wedbush, 37.50%) | Buy |
| Average | 63.43 (98.22%) | |
| Total | 4 Buy, 3 Hold | |
| Avg. Price @ Call | 35.02 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 15 Oct 2024 | 60.00 (87.50%) | Hold | 38.90 |
| 18 Sep 2024 | 80.00 (150.00%) | Buy | 29.31 | |
| Truist Securities | 15 Oct 2024 | 60.00 (87.50%) | Hold | 38.90 |
| 10 Sep 2024 | 60.00 (87.50%) | Buy | 35.33 | |
| B. Riley Securities | 14 Oct 2024 | 60.00 (87.50%) | Hold | 38.90 |
| Wedbush | 17 Sep 2024 | 44.00 (37.50%) | Buy | 27.58 |
| 02 Aug 2024 | 40.00 (25.00%) | Buy | 32.85 | |
| Cantor Fitzgerald | 16 Sep 2024 | 90.00 (181.25%) | Buy | 30.74 |
| 02 Aug 2024 | 90.00 (181.25%) | Buy | 32.85 | |
| Evercore ISI Group | 26 Aug 2024 | 80.00 (150.00%) | Buy | 37.27 |
| Citigroup | 02 Aug 2024 | 50.00 (56.25%) | Buy | 32.85 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |